Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
-
Published:2021-07
Issue:4
Volume:28
Page:328-336
-
ISSN:1548-5595
-
Container-title:Advances in Chronic Kidney Disease
-
language:en
-
Short-container-title:Advances in Chronic Kidney Disease
Author:
Tricò Domenico,
Solini AnnaORCID
Reference75 articles.
1. Are all GLP-1 agonists equal in the treatment of type 2 diabetes?;Nauck;Eur J Endocrinol,2019
2. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art;Nauck;Mol Metab,2020
3. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes;Nielsen;Regul Pept,2004
4. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects;Elbrond;Diabetes Care,2002
5. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes;Kim;Diabetes Care,2007
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献